AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,181,438 | +335.5% | 10,376,763 | +349.9% | 0.42% | +350.5% |
| Q2 2023 | $28,971,712 | +14.5% | 2,306,665 | +1.1% | 0.09% | +5.7% |
| Q1 2023 | $25,297,310 | -1.4% | 2,281,092 | +8.6% | 0.09% | -10.2% |
| Q4 2022 | $25,655,481 | +17.8% | 2,101,186 | +0.8% | 0.10% | +14.0% |
| Q3 2022 | $21,771,000 | -20.4% | 2,085,364 | -18.1% | 0.09% | -14.9% |
| Q2 2022 | $27,361,000 | +14.1% | 2,547,606 | +0.6% | 0.10% | +40.3% |
| Q1 2022 | $23,972,000 | -16.2% | 2,531,412 | +2.2% | 0.07% | -6.5% |
| Q4 2021 | $28,606,000 | +51.7% | 2,476,721 | +25.4% | 0.08% | +45.3% |
| Q3 2021 | $18,861,000 | +0.2% | 1,974,972 | +1.2% | 0.05% | -10.2% |
| Q2 2021 | $18,814,000 | +64.1% | 1,951,677 | +68.1% | 0.06% | +59.5% |
| Q1 2021 | $11,468,000 | -53.7% | 1,160,724 | +8.3% | 0.04% | -54.9% |
| Q4 2020 | $24,744,000 | +81.4% | 1,071,651 | +11.0% | 0.08% | +54.7% |
| Q3 2020 | $13,637,000 | – | 965,763 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |